News
Media
Conferences
Publications
Events
CME/CE
Resources
Career Center
Subscribe

Your AI-Trained Oncology Knowledge Connection!

|Videos|December 8, 2022

Case Presentation: A 69-Year-Old Woman with HER2+ Metastatic Breast Cancer (mBC)

Author(s)Joyce O’Shaughnessy, MD, Virginia Kaklamani, MD, DSc, Heather McArthur, MD, MPH

Heather McArthur, MD, presents the case of a 69-year-old woman with stage II HER2+ mBC for discussion.

Episodes in this series

EP. 1 Case Presentation: A 69-Year-Old Woman with HER2+ Metastatic Breast Cancer (mBC)

EP. 1 Case Presentation: A 69-Year-Old Woman with HER2+ Metastatic Breast Cancer (mBC)

EP. 2 Trastuzumab Deruxtecan Maintenance after First-Line Therapy for HER2+ mBC

EP. 2 Trastuzumab Deruxtecan Maintenance after First-Line Therapy for HER2+ mBC

EP. 3 Screening for Brain Metastases in HER2+ Breast Cancer

EP. 3 Screening for Brain Metastases in HER2+ Breast Cancer

EP. 4 Third-Line Treatment Options for HER2+ mBC after Progression on Trastuzumab Deruxtecan

EP. 4 Third-Line Treatment Options for HER2+ mBC after Progression on Trastuzumab Deruxtecan

EP. 5 Case Presentation: A 60-Year-Old Woman with HER2+ mBC with Brain Metastases

EP. 5 Case Presentation: A 60-Year-Old Woman with HER2+ mBC with Brain Metastases

EP. 6 Treatment Approaches in HER2+ mBC with Brain Metastases

EP. 6 Treatment Approaches in HER2+ mBC with Brain Metastases

EP. 7 Managing Adverse Events of Tucatinib in Patients with HER2+ mBC with Brain Metastases

EP. 7 Managing Adverse Events of Tucatinib in Patients with HER2+ mBC with Brain Metastases

EP. 8 Leptomeningeal Metastases in HER2+ mBC

EP. 8 Leptomeningeal Metastases in HER2+ mBC

EP. 9 Systemic Therapy Before Whole Brain Radiation for HER2+ mBC with Brain Metastases

EP. 9 Systemic Therapy Before Whole Brain Radiation for HER2+ mBC with Brain Metastases

EP. 10 Case Presentation: A 62-Year-Old Woman with HER2+ mBC with Pulmonary and Brain Metastases

EP. 10 Case Presentation: A 62-Year-Old Woman with HER2+ mBC with Pulmonary and Brain Metastases

EP. 11 Future Perspectives in HER2+ mBC

EP. 11 Future Perspectives in HER2+ mBC

Recap: HER2+ Breast Cancer and Brain Metastases: Challenges and Treatments

EP. 12 Recap: HER2+ Breast Cancer and Brain Metastases: Challenges and Treatments

Newsletter

Stay up to date on recent advances in the multidisciplinary approach to cancer.

Related Content

The addition of zovegalisib to fulvestrant led to rapid declines in PIK3CA and ESR1 ctDNA in the HR-positive/HER2-negative advanced breast cancer group.

Zovegalisib Combo Confers Efficacy Benefit in PIK3CA-Mutated Breast Cancer

ByRoman Fabbricatore

December 28th 2025

Safety data from ASCENT-03 support sacituzumab govitecan as an effective therapy with manageable toxicities in advanced triple-negative breast cancer.

Sacituzumab Govitecan Yields Fewer AEs Vs Chemotherapy in Advanced TNBC

December 24th 2025

Why is Lymphedema Detected So Late in Breast Cancer?

ByKandance P. McGuire, MD, FACS

December 24th 2025

Exploratory data from a phase 3 study may help optimize adjuvant endocrine therapy choices in hormone receptor–positive, HER2-positive breast cancer.

Breast Cancer Data Affirm Aromatase Inhibitors as Optimal Endocrine Therapy

ByAndrea Eleazar, MHS

December 23rd 2025

Results from the DESTINY-Breast05 trial revealed that T-DXd was superior to T-DM1 in these patients with HER2-positive early breast cancer.

FDA Grants BTD to T-DXd in HER2+ BC With Residual Invasive Disease Post NAT

December 22nd 2025

Trending on CancerNetwork

Spotlighting the Top 10 FDA Oncology Approvals in 2025

A Look Back on the Top 10 Oncology Interviews in 2025

Zovegalisib Combo Confers Efficacy Benefit in PIK3CA-Mutated Breast Cancer

Why is Lymphedema Detected So Late in Breast Cancer?

The Evolution of Distress Screening in Cancer Care